FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)																
Name and Address of Reporting Person * BAKER BROS. ADVISORS LP				2. Issuer Name and Ticker or Trading Symbol XOMA Corp [XOMA]						_X_ Dir	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ 10% Owner					
667 MADISON AVENUE	, 21ST FLOOR	(M	iddle)	3. Date o 01/02/2	f Earliest Transact 015	ion (Month/Day/Y	ear)				Off	fficer (give title below)	Ot	ther (specify below)		
NEW YORK, NY US 1000	(Street)			4. If Ame	endment, Date Ori	ginal Filed(Month/Da	y/Year)				Form	vidual or Joint/Group Filing(Check in filed by One Reporting Person in filed by More than One Reporting Person				
(City)	(State)		(Zip)				Table	I - Non-Dei	ivative S	ecurities Acq	quired, Dis	sposed of, or Beneficially Own	ed			
1.Title of Security (Instr. 3)		2. Transact (Month/Da			f (Instr. 8)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		ing Reported	Form:	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) or (D)	Price					or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock			01/02/20	15		S		25,092	D	\$ 3.5537 (1)	7 2,089	9,012			I	See footnote (2) (6)
Common Stock			01/02/20	15		S		182,454	D	\$ 3.5537 (1)	7 14,31	13,038			I	See footnote (3) (6)
Common Stock			01/02/20	15		s		4,554	D	\$ 3.5537 (1)	7 388,0	.063			I	See footnote (4) (6)
Common Stock			01/05/20	15		S		118,652	D	\$ 3.8115 (5)	5 1,970	70,360			I	See footnote (2) (6)
Common Stock			01/05/20	15		S		863,100	D	\$ 3.8115 (5)	5 13,44	49,938			I	See footnote (3) (6)
Common Stock			01/05/20	15		S		21,548	D	\$ 3.8115 (5)	366,5	.515			I	See footnote (4) (6)
Common Stock			01/06/20	15		S		118,571	D	\$ 3.86	1,851	1,789			I	See footnote (2) (6)
Common Stock			01/06/20	15		S		859,988	D	\$ 3.86	12,58	89,950			I	See footnote (3) (6)
Common Stock			01/06/20	15		S		21,441	D	\$ 3.86	345,0	074			I	See footnote (4) (6)
Reminder: Report on a separate l	ine for each class of	securities beneficially	owned directly or	indirectly.			Persons	who reend	nd to the	e collection	n of inform	mation contained in this for	m are not rea	nuired to	SEC	1474 (9-02)
												alid OMB control number.	are not let	qu60 to	SEC	(>-02)
				Tab	ole II - Derivative	Securities Acquir				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	(Instr.	nsaction Code 8)	5. Number of Deri Securities Acquire Disposed of (D) Instr. 3, 4, and 5)	ative	6. Date l Expiration	Exercisabl	Sec	Title and Arcurities	amount of Underlying	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				C	'ode V	(A)	(D)	Date Exercisa		piration Title	tle Amou	ount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
BAKER BROS. ADVISORS LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X					
667, L.P. 667 MADISON AVENUE 21ST FLOOR NEW YORK, NY US 10065	X	X					
Baker Brothers Life Sciences LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X					
14159, L.P. 667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X					
Baker Bros. Advisors (GP) LLC 667 MADISION AVENUE 21ST FLOOR NEW YORK, NY US 10065	X	X					
BAKER FELIX 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X					
BAKER JULIAN 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X					

Signatures

By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing Title: President /s/ Scott L. Lessing		01/06/2015	
	4	_	

Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing	01/06/2015
**Signature of Reporting Person	Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P. Name: Scott L. Lessing, Title: President/s/	01/06/2015
**Signature of Reporting Person	Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 14159, L.P., pursuant to authority granted by 14159 Capital, L.P., GP to 14159, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing	01/06/2015
**Signature of Reporting Person	Date
Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing Title: President /s/ Scott L. Lessing	01/06/2015
**Signature of Reporting Person	Date
/s/ Felix J. Baker	01/06/2015
**Signature of Reporting Person	Date
/s/ Julian C. Baker	01/06/201:
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The price reported in Column 4 is a weighted average price. These shares were sold by each of Baker Brothers Life Sciences, L.P. ("Life Sciences"), 14159, L.P. ("14159"), and 667, L.P. ("667", and together with Life Sciences and 14159, the "Funds") in multiple transactions at prices rate the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- (2) After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- (3) After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock report Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., is right to receive an allocation of a portion of the profits from Life Sciences.
- (4) After giving effect to the transactions reported herein and as a result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Tab partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold by the Funds in multiple transactions at prices ranging from \$3.70 to \$3.98, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Security price within the range set forth in this footnote.
- Baker Bros. Advisors LP ("the Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors LP ("the Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and dispositive power over the stock options and restricted stock units received by Dr. Neu related to his service on the Board of Directors of the Issuer (the "Board") and any shares received as a result of the exercise of stock options or the ves Neu does not have any right to any of the Issuer's securities issued a part of his service on the Board, and the Funds are entitled to receive all the pecuniary interest in the securities issued. Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser GP or

Remarks:

Dr. Kelvin Neu, an employee of Baker Bros. Advisors LP, is a director of Xoma Corporation (the "Issuer"). By virtue of his representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.